Outgro Pain Relief Shortage: What Providers and Prescribers Need to Know in 2026

Providers whose patients ask about Outgro Pain Relief in 2026 are facing an unusual situation: a long-established OTC product that has quietly been discontinued from most major pharmacy chains without any official FDA shortage designation. This post provides the clinical background, regulatory context, and evidence-based guidance providers need to counsel patients appropriately.

Clinical Overview: What Is Outgro Pain Relief?

Outgro Pain Relief (MedTech Products Inc.) is a topical OTC liquid containing benzocaine 20% w/v as its active ingredient, with inactive ingredients including alcohol, PEG-400, and colorants. It is supplied in a 0.31 fl oz (9.3 mL) bottle with an integrated brush applicator.

Benzocaine is an ester-type local anesthetic. Applied topically, it reversibly blocks voltage-gated sodium channels in nociceptive nerve endings, preventing depolarization and signal propagation. Onset is rapid (1-2 minutes) and duration is approximately 10 minutes per application. Maximum dosing is 3-4 times daily.

FDA Regulatory History: Why Outgro's Claims Changed

Providers should be aware of the FDA OTC monograph history that shaped Outgro's current labeling:

1982 TFM: FDA classified tannic acid and sodium sulfide as Category III (data insufficient) for ingrown toenail use. Benzocaine, chlorobutanol, and dibucaine were noted as anesthetic ingredients of interest.

1993-1994 Final Rule: FDA issued its final monograph for ingrown toenail products, finding no monograph ingredients — no topical anesthetic (including benzocaine) had established efficacy for ingrown toenail pain. Any product marketed for that specific use became an unapproved new drug. Outgro's original formula (tannic acid + chlorobutanol) was effectively removed from the market.

Reformulation: The manufacturer reformulated to benzocaine 20% and relabeled the product for "minor skin irritations" of the foot rather than ingrown toenail pain — an attempt to remain marketable while complying with FDA findings.

2003 FDA Final Rule: FDA approved sodium sulfide 1% in gel vehicle as safe and effective for temporary relief of ingrown toenail pain — the first ingredient to receive this designation. This approval paved the way for Dr. Scholl's Ingrown Toenail Pain Reliever and further marginalized Outgro in the foot care market.

FDA Safety Communications on Benzocaine

Providers should be familiar with FDA's benzocaine safety communications, which have further complicated the product's retail standing:

The FDA has documented over 400 cases of benzocaine-associated methemoglobinemia reported since 1971

In 2018, FDA required updated labeling with standardized methemoglobinemia warnings on OTC benzocaine products

Contraindications were added for use in children under 2 years and for teething applications

High-risk populations include those with breathing disorders (asthma, COPD, emphysema), heart disease, G6PD deficiency, pyruvate kinase deficiency, and smokers

Evidence-Based Alternatives to Recommend to Patients

When counseling patients who ask about Outgro, providers should distinguish between the underlying condition:

For ingrown toenail pain:

Dr. Scholl's Ingrown Toenail Pain Reliever (sodium sulfide 1% gel) — the only OTC ingredient with FDA monograph approval for ingrown toenail pain. Mechanism: softens the skin tissue around the nail edge to reduce pressure and pain.

Conservative measures: warm water soaks, proper toenail trimming technique, appropriate footwear

Podiatric referral for recurrent, severe, or infected ingrown toenails (onychocryptosis)

For general foot skin irritation:

Generic benzocaine 20% topical liquid — therapeutically equivalent to Outgro; widely available as store brands

Dermoplast spray (benzocaine 20% + menthol 0.5%) — same active ingredient; widely available

LMX 4 (lidocaine 4% cream) — amide-type anesthetic alternative for patients with ester anesthetic sensitivity; longer duration (30-60 minutes)

Patient Counseling Points

Clarify that the current Outgro formula (benzocaine 20%) is NOT FDA-approved to treat ingrown toenail pain — it is labeled for minor skin irritations only

Warn about methemoglobinemia risk — particularly in patients with pulmonary disease, cardiac disease, G6PD deficiency, or who are elderly

Patients should stop use and seek care if skin condition worsens or does not improve within 7 days

Outgro is extremely flammable — alcohol-based; patients should not smoke during use or near open flame

Helping Patients Locate Outgro or Equivalents

For patients set on finding Outgro specifically, or providers managing patients with complex medication access challenges, medfinder for providers offers a service that calls local pharmacies to check which ones have a medication in stock and texts the results to the patient. This can save patients significant time and frustration when a product is hard to locate.

For a full clinical comparison of alternatives, see: Alternatives to Outgro Pain Relief